# Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/adjunctive-everolimus-therapy-for-treatment-resistant-focal-onset-seizures/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jacqueline A. French,John A. Lawson,Zühal Yapıcı,Hiroko Ikeda,Tilman Polster,Rima Nabbout,Paolo Curatolo,Petrus J. de Vries,Dennis Dlugos,Noah Berkowitz,Maurizio Voi,Séverine Peyrard,Diana Pelov,David Neal Franz |
| Citations | 754 |
| DOI | 10.1016/s0140-6736(16)31419-2 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.thelancet.com/article/S0140673616314192/pdf |
| OpenAlex ID | https://openalex.org/W2511912940 |
| PMID | 27613521 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Rima Nabbout](https://scholariq.org/researchers/rima-nabbout/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Tuberous Sclerosis Complex Research](https://scholariq.org/topics/tuberous-sclerosis-complex-research/)

## Paper topics

- [Tuberous Sclerosis Complex Research](https://scholariq.org/topics/tuberous-sclerosis-complex-research/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.